SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin inks strategic deal with NeuClone for cell line technology

01 Jun 2011 Evaluate

Pharma major, Lupin has entered into a strategic licensing agreement with Sydney based private specialty life science company NeuClone for their cell line technology.

Under the terms of the agreement, NeuClone will provide an exclusive proprietary mammalian CHO cell line which will express a specific recombinant protein of interest in oncology to its partner. The agreement will also entail the Lupin Biological Research program scientific research staff working with NeuClone terms at their facility as per a part of the overall technology transfer arrangements as specified within the agreement. This exclusive licensing agreement with NeuClone is a part of that strategy and would enable Lupin to capitalize on cutting edge technology to address the biological markets.

Lupin is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs.

NeuClone is an Australian biotech company specializing in cell line engineering for the bio-pharmaceutical and bio-manufacturing industries. NeuClone has developed technology in recombinant protein production.

Lupin Share Price

2377.90 -81.85 (-3.33%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×